Unexpected Nanomolar Inhibition of Carbonic Anhydrase by COX-2-Selective Celecoxib: New Pharmacological Opportunities Due to Related Binding Site Recognition

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 550-557

  Weber, Alexander ^a   Casini, Angela ^b   Heine, Andreas ^a   Kuhn, Daniel ^a   Supuran, Claudiu T ^b   Scozzafava, Andrea ^b   Klebe, Gerhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 BROMOPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETAZOLAMIDE; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IV; CARBONATE DEHYDRATASE IX; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DICLOFENAMIDE; DORZOLAMIDE; ETHOXZOLAMIDE; ISOENZYME; METHAZOLAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; ROFECOXIB; SC 125; SULFONAMIDE; UNCLASSIFIED DRUG; VALDECOXIB; ZINC;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER THERAPY; CROSS REACTION; CRYSTAL STRUCTURE; DATA BASE; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; GLAUCOMA; INTRAOCULAR PRESSURE; MOLECULAR RECOGNITION; NONHUMAN; PHYSICAL CHEMISTRY; RABBIT; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 2; INTRAOCULAR PRESSURE; ISOENZYMES; ISOXAZOLES; KINETICS; LACTONES; MODELS, MOLECULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONES;

EID: 1642540579     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030912m     Document Type: Article

References (43)

1. Vane, J. R.; Bakhle, Y. S.; Botting, R. M. Cyclooxygenases 1 and 2. Annu Rev. Pharmacol. Toxicol. 1998, 38, 97-120.
2. Narumiya, S.; FitzGerald, G. A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 2001, 108, 25-30.
3. Tilley, S. L.; Coffman, T. M.; Koller, B. H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 2001, 108, 15-23.
4. McAdam, B. F.; Catella-Lawson, F.; Mardini, I. A.; Kapoor, S.; Lawson, J. A. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 272-7.
5. Harris, R. C.; Breyer, M. D. Physiological regulation of cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal Physiol. 2001, 281, F1-11.
6. Morteau, O.; Morham, S. G.; Sellon, R.; Dieleman, L. A.; Langenbach, R. et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest. 2000, 105, 469-78.
7. Warner, T. D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J. A. et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo- oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 7563-8.
8. Masferrer, J. L.; Zweifel, B. S.; Seibert, K.; Needleman, P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. 1990, 86, 1375-9.
9. Chan, C. C.; Boyce, S.; Brideau, C.; Charleson, S.; Cromlish W. et al. Rofecoxib [Vioxx, MK-0966; 4-(4′ -methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 1999, 290, 551-60.
10. Zhang, Y.; Shaffer, A.; Portanova, J.; Seibert, K.; Isakson, P. C. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J. Pharmacol. Exp. Ther. 1997, 283, 1069-75.
11. Simon, L. S.; Weaver, A. L.; Graham, D. Y.; Kivitz, A. J.; Lipsky, P. E. et al. Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999, 282, 1921-8.
12. Hawkey, C.; Laine, L.; Simon, T.; Beaulieu, A.; Maldonado-Cocco, J. et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. 2000, 43, 370-7.
13. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000, 343, 1520-8, 2 p following 1528.
14. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284, 1247-55.
15. FitzGerald, G. A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-42.
16. Whelton, A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001, 110 Suppl. 3A, 33S-42S.
17. Whelton, A.; Fort, J. G.; Puma, J. A.; Normandin, D.; Bello, A. E. et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 2001, 8, 85-95.
18. Whelton, A.; White, W. B.; Bello, A. E.; Puma, J. A.; Fort, J. G. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. 2002, 90, 959-63.
19. Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146-89.
20. Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Pat. 2000, 10, 575-600.
21. Abbate, F.; Supuran, C. T.; Scozzafava, A.; Orioli, P.; Stubbs, M. T. et al. Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J. Med. Chem. 2002, 45, 3583-7.
22. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A. et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384, 644-8.
23. Smith, G. M.; Alexander, R. S.; Christianson, D. W.; McKeever, B. M.; Ponticello, G. S. et al. Positions of His-64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors. Protein Sci. 1994, 3, 118-25.
24. Pastorek, J.; Pastorekova, S.; Callebaut, I.; Momon, J. P.; Zelnik, V. et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix- loop-helix DNA binding segment. Oncogene 1994, 9, 2877-88.
25. Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A. et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005-9.
26. Lindskog, S. Structure and mechanism of carbonic anhydrase. Pharmacol. Ther. 1997, 74, 1-20.
27. Liljas, A.; Hakansson, K.; Jonsson, B. H.; Xue, Y. Inhibition and catalysis of carbonic anhydrase. Recent crystallographic analyses. Eur. J. Biochem. 1994, 219, 1-10.
28. Schmitt, S.; Hendlich, M.; Klebe, G. From Structure to Function: A New Approach to Detect Functional Similarity among Proteins Independent from Sequence and Fold Homology. Angew. Chem., Int. Ed. 2001, 40, 3141-4.
29. Schmitt, S.; Kuhn, D.; Klebe, G. A new method to detect related function among proteins independent of sequence and fold homology. J. Mol. Biol. 2002, 323, 387-406.
30. Flower, R. J. Case history: The development of COX2 inhibitors. Nat. Rev. Drug Discovery 2003, 2, 179-91.
31. Boriack-Sjodin, P. A.; Zeitlin, S.; Chen, H. H.; Crenshaw, L.; Gross, S. et al. Structural analysis of inhibitor binding to human carbonic anhydrase II. Protein Sci. 1998, 7, 2483-9.
32. Folkers, G.; Klein, C. D. P. Computational Methods Facilitate the Assignment of Protein Functions. Angew. Chem., Int. Ed. 2001, 40, 4175-7.
33. Kawamori, T.; Rao, C. V.; Seibert, K.; Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998, 58, 409-12.
34. Oshima, M.; Murai, N.; Kargman, S.; Arguello, M.; Luk, P. et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 2001, 61, 1733-40.
35. Waskewich, C.; Blumenthal, R. D.; Li, H.; Stein, R.; Goldenberg, D. M. et al. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002, 62, 2029-33.
36. Warner, T. D.; Mitchell, J. A. Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: As easy ABC? Proc. Natl. Acad. Sci. 2003, 100, 9108-9110.
37. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276A, 307-326.
38. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P. et al. Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallogr. D 1998, 54, 905-921.
39. Sheldrick, G. M.; Schneider, T. R. SHELXL: High-Resolution Refinement. Methods Enzymol. 1997, 277A, 319-343.
40. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 1991, 47, 110-9.
41. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, 2002.
42. Hakansson, K.; Liljas, A. The structure of a complex between carbonic anhydrase II and a new inhibitor, trifluoromethane sulphonamide. FEBS Lett. 1994, 350, 319-22.
43. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.